Related Experiment Video

Updated: Jul 15, 2025

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.9K

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer

Peixin Chen1,2, Chenglong Sun3, Hao Wang1,2

  • 1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.

Cell Death & Disease
|September 26, 2023
PubMed

Insights

Targeting YAP1 in small cell lung cancer (SCLC) offers a new strategy to enhance immunotherapy. Blocking YAP1 in the SCLC-Y subtype improves anti-tumor immune responses and patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Small cell lung cancer (SCLC) is highly malignant and heterogeneous, limiting immunotherapy efficacy.
  • Novel combination strategies are needed to improve SCLC treatment outcomes.
  • SCLC exhibits significant molecular heterogeneity, necessitating subtype-specific therapeutic approaches.

Purpose of the Study:

  • To classify SCLC subtypes based on key transcription factor expression.
  • To investigate the role of YAP1 in SCLC immune evasion and therapeutic response.
  • To evaluate YAP1 blockade as a strategy to enhance immunotherapy in SCLC.

Main Methods:

  • Immunofluorescence-based classification of 100 SCLC patients into SCLC-A, SCLC-N, SCLC-P, and SCLC-Y subtypes.
  • Analysis of clinical outcomes, tumor microenvironment, and immunotherapy sensitivity across subtypes.
  • In vitro experiments to assess the impact of YAP1 blockade on cancer cells and immune cells.

Main Results:

  • SCLC-Y subtype (high YAP1 expression) showed the worst clinical outcome.
  • SCLC-Y tumors exhibited high PD-L1, stromal score, and impaired T-cell function.
  • YAP1 upregulation suppressed T-cell activation and promoted immune evasion.
  • YAP1 blockade in vitro enhanced apoptosis, immune cell proliferation, and T-cell activation.

Conclusions:

  • SCLC exhibits distinct molecular subtypes with varying prognoses and immunotherapy responses.
  • The SCLC-Y subtype is characterized by YAP1-driven immune evasion.
  • Targeting YAP1 presents a promising strategy to overcome immunotherapy resistance in SCLC-Y patients.

More Related Videos

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

3.0K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K